



Biogen Submits Response to the Centers for Medicare and Medicaid Services (CMS) Proposed National Coverage Determination (NCD) for Anti-Amyloid Treatments in Alzheimer's Disease

February 10, 2022

[Read Biogen's response to CMS here.](#)